{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-266717","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-06-11T12:00:15+00:00","discovered_at":"2026-06-11T12:05:00.345202+00:00","generated_at":"2026-06-11T12:05:36.664560+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa raises $4.5M in registered direct offering of stock and warrants","bullets":["Sold 1,363,638 shares at $3.30/share plus Series A and B warrants for 1,363,638 shares each at $4.40.","Net proceeds ~$4.1M; expected close June 12, 2026; funds for clinical development and working capital.","Placement agent gets 7% cash fee plus warrants for 123,000 shares at $4.125.","Series A warrants expire in 5.5 years, Series B in 2 years; exercise begins 6 months after issuance.","Potential additional gross proceeds of ~$12M if fully exercised, but no assurance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-266717","json":"https://secwatch.observer/filing/0001193125-26-266717.json","markdown":"https://secwatch.observer/filing/0001193125-26-266717.md","text":"https://secwatch.observer/filing/0001193125-26-266717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/0001193125-26-266717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:05:36.664560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"209049fb07948eedf02451f008574aee68bb249f","claim":"ATOSSA THERAPEUTICS, INC. entered into Purchase Agreement with institutional investors valued at approximately $4.1 million (effective 2026-06-10).","evidence_excerpt":"On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/0001193125-26-266717-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors"},{"label":"Value","value":"approximately $4.1 million"},{"label":"Effective","value":"2026-06-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}